Genital Herpes Pipeline Therapeutic Assessment Review H2 2015 - PowerPoint PPT Presentation

jack2222simon
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Genital Herpes Pipeline Therapeutic Assessment Review H2 2015 PowerPoint Presentation
Download Presentation
Genital Herpes Pipeline Therapeutic Assessment Review H2 2015

play fullscreen
1 / 6
Download Presentation
Genital Herpes Pipeline Therapeutic Assessment Review H2 2015
153 Views
Download Presentation

Genital Herpes Pipeline Therapeutic Assessment Review H2 2015

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Genital Herpes - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 26-Aug-2015 No. of pages: 100 Single User License: US $2000 Browse more Reports on Sexually Transmitted Diseases Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/sexually-transmitted-diseases-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Genital Herpes - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Genital Herpes - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Admedus Ltd, AiCuris GmbH & Co. KG, AlphaVax, Inc., Foamix Pharmaceuticals Ltd., Genocea Biosciences, Inc., GenVec, Inc., Immune Design Corp., Immunovaccine, Inc., Mymetics Corporation, NanoBio Corporation, NanoViricides, Inc., PaxVax, ProfectusBioSciences, Inc., Sanofi Pasteur SA, Spider Biotech, Starpharma Holdings Limited, Vaccibody AS, Vaxart, Inc. and Vical Incorporated Drugs Profile Discussed in this Research: acyclovir, Aspidasept, astodrimer, G-103, GEN-002, GEN-003, genital herpes vaccine [HSV-2], GV-2207, HerpeCide-I, herpes simplex virus [serotype 2] vaccine, herpes simplex virus [type 1, 2] vaccine, herpes simplex virus [type 2] vaccine, herpes simplex virus [type 2] vaccine, herpes simplex virus [type 2] vaccine, herpes simplex virus [type 2] vaccine, HSV-529, pritelivir, SB-105A10, VCLHB-01 and VCLHM-01 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Genital Herpes - Pipeline Review, H2 2015 Scope For Genital Herpes - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Genital Herpes • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Genital Herpes - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Genital Herpes • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Genital Herpes - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441